# Kewaunee Scientific (KEQU) Q1 2026 Financial Results Summary
Kewaunee Scientific Corporation (NASDAQ: KEQU) announced its financial results for the first quarter of fiscal year 2026 on September 10, 2025. The results reflect the quarter ended July 31, 2025.
## Key Financial Highlights
– **Total Sales**:
– Q1 FY2026: **$71,104,000**
– Increase of **46.9%** from **$48,393,000** in Q1 FY2025.
– **Pre-tax Earnings**:
– Q1 FY2026: **$3,920,000**
– Increased by **61.3%** from **$2,430,000** in the prior year quarter.
– **Net Earnings**:
– Q1 FY2026: **$3,093,000**
– Growth of **41.1%** from **$2,193,000** in Q1 FY2025.
– **EBITDA**:
– Q1 FY2026: **$6,320,000**
– Increased by **90.0%** from **$3,325,000** in Q1 FY2025.
– **Diluted Earnings per Share (EPS)**:
– Q1 FY2026: **$1.04**
– Up from **$0.74** in Q1 FY2025, representing an increase of **40.5%**.
– **Order Backlog**:
– As of July 31, 2025: **$205.0 million**
– Compared to **$159.4 million** as of July 31, 2024.
## Segment Performance
### Domestic Segment
– **Sales**:
– Q1 FY2026: **$54,352,000**
– Up by **53.0%** from **$35,523,000** in the prior year quarter.
– **Net Earnings**:
– Q1 FY2026: **$4,722,000**
– Increased from **$2,871,000** in the prior year quarter.
– **EBITDA**:
– Q1 FY2026: **$7,576,000**
– Up from **$4,738,000** in Q1 FY2025.
### International Segment
– **Sales**:
– Q1 FY2026: **$16,752,000**
– Increased by **30.2%** from **$12,870,000** in Q1 FY2025.
– **Net Earnings**:
– Q1 FY2026: **$643,000**
– Compared to **$463,000** in the prior year quarter.
– **EBITDA**:
– Q1 FY2026: **$1,055,000**
– Increased from **$696,000** in Q1 FY2025.
### Corporate Segment
– **Pre-tax Net Loss**:
– Q1 FY2026: **$3,058,000**
– Higher loss compared to **$1,992,000** in the prior year quarter.
– **EBITDA**:
– Q1 FY2026: **($2,311,000)**
– Slightly more than **($2,109,000)** in Q1 FY2025.
## Financial Position
– **Cash on Hand**:
– As of July 31, 2025: **$20,441,000**
– Up from **$17,164,000** on April 30, 2025.
– **Working Capital**:
– Q1 FY2026: **$66,662,000**
– Compared to **$56,012,000** at the end of the first quarter last year.
– **Debts**:
– **Short-term Debt**: **$4,294,000** (down from **$4,773,000** on April 30, 2025).
– **Long-term Debt**: **$60,269,000** (down from **$60,730,000** on April 30, 2025).
– **Debt-to-Equity Ratio**:
– Q1 FY2026: **0.94-to-1** compared to **0.99-to-1** on April 30, 2025.
## Dividends and Share Repurchase
– The report did not indicate any declaration of a quarterly dividend or share repurchase.
## Outlook and Strategy
– Kewaunee’s President and CEO Thomas D. Hull III highlighted the solid performance of domestic and international segments despite challenging market conditions.
– The company is focused on growth and intends to make strategic investments in personnel, processes, and technology.
– While they expect variability in project delivery timelines, they aim to improve unadjusted EBITDA in FY2026 compared to FY2025.
For more details regarding Kewaunee Scientific Corporation, further reports, and strategic updates, please visit their official website.
| Three Months Ended | ||
|---|---|---|
| July 31, | ||
| 2025 | 2024 | |
| Net sales | $71,104 | $48,393 |
| Cost of products sold | 50,174 | 35,905 |
| Gross profit | 20,930 | 12,488 |
| Operating expenses | 16,120 | 9,913 |
| Operating profit | 4,810 | 2,575 |
| Other income, net | 168 | 327 |
| Interest expense | -1,058 | -472 |
| Profit before income taxes | 3,920 | 2,430 |
| Income tax expense | 761 | 192 |
| Net earnings | 3,159 | 2,238 |
| Less: Net earnings attributable to the | 66 | 45 |
| non-controlling interest | ||
| Net earnings attributable to Kewaunee | $3,093 | $2,193 |
| Scientific Corporation | ||
| Net earnings per share attributable to | ||
| Kewaunee Scientific Corporation | ||
| stockholders | ||
| Basic | $1.08 | $0.77 |
| Diluted | $1.04 | $0.74 |
| Weighted average number of common shares | ||
| outstanding | ||
| Basic | 2,851 | 2,849 |
| Diluted | 2,963 | 2,967 |
—
| July 31, 2025 | April 30, 2025 | |
|---|---|---|
| Assets | ||
| Cash and cash equivalents | $19,489 | $14,942 |
| Restricted cash | 952 | 2,222 |
| Receivables, less allowances | 56,897 | 62,384 |
| Inventories | 34,923 | 32,849 |
| Prepaid expenses and other current | 4,887 | 5,966 |
| assets | ||
| Total Current Assets | 117,148 | 118,363 |
| Net property, plant and equipment | 22,781 | 23,174 |
| Right of use assets | 12,022 | 12,965 |
| Deferred income taxes | 4,211 | 3,994 |
| Net intangible assets | 17,447 | 17,831 |
| Goodwill | 12,487 | 12,487 |
| Other assets | 7,390 | 5,840 |
| Total Assets | $193,486 | $194,654 |
| Liabilities and Stockholders’ Equity | ||
| Short-term borrowings | $495 | $986 |
| Current portion of lease obligations | 3,220 | 3,371 |
| Current portion of financing liability | 807 | 788 |
| Current portion of term loan | 2,903 | 2,903 |
| Accounts payable | 26,327 | 27,033 |
| Other current liabilities | 16,734 | 18,631 |
| Total Current Liabilities | 50,486 | 53,712 |
| Long-term portion of lease obligations | 8,156 | 8,946 |
| Long-term portion of financing liability | 26,420 | 26,632 |
| Long-term portion of seller note | 24,021 | 23,537 |
| Long-term portion of term loan | 9,686 | 10,412 |
| Other non-current liabilities | 5,848 | 5,170 |
| Total Liabilities | 124,617 | 128,409 |
| Kewaunee Scientific Corporation Equity | 67,078 | 64,457 |
| Non-controlling interest | 1,791 | 1,788 |
| Total Stockholders’ Equity | 68,869 | 66,245 |
| Total Liabilities and Stockholders’ | $193,486 | $194,654 |
| Equity |
